Exin Therapeutics Analysis: $500K Raised

Exin Therapeutics develops a discovery platform for genetic therapies targeting dysregulated neural circuits across disorders. Their neurotherapeutics utilize advancements in genetics and technology to create treatments for neurological disorders. The company focuses on gene therapy, nucleotide-based therapeutics, and cell-based therapies to address previously untreatable disease mechanisms.

Target dysregulated neural circuits in neurological disorders; Develop treatments for previously untreatable diseases; Utilize machine learning for therapeutic discovery; Implement genome editing techniques; Leverage bioelectronic medicine for treatment solutions

Backed by Y Combinator; Focused on addressing unmet medical needs in neurology; Active in the biotechnology sector